ACRV News
Archived Headlines
- US IPO Weekly Recap: Chinese hotel chain leads a 3 IPO week 11/11/22
- US IPO Week Ahead: Biotech IPOs set to brave challenging market conditions 11/04/22
- US IPO Weekly Recap: No IPOs, but another sizable biotech joins the calendar 11/04/22
- Oncology biotech Acrivon Therapeutics sets terms for $100 million IPO 11/03/22
- Renaissance Capital's October IPO Market Update 11/01/22
See more
Renaissance Capital's November IPO Market Update
It was the IPO market's slowest November in six years as just four deals raised a combined $166 million. The month's lineup was led by $50+ million IPOs, biotech Acrivon Therapeutics (ACRV) and Chinese hotel chain ...read more
US IPO Weekly Recap: Biotech Acrivon completes the week’s sole IPO while big deals join the pipeline
After delaying its offering, Acrivon Therapeutics (ACRV) completed the week’s sole IPO. In the pipeline, seven companies submitted initial filings, including three planning to raise $100 million. Biotech ...read more
Oncology biotech Acrivon Therapeutics prices IPO at $12.50, well below the range
Acrivon Therapeutics, a Phase 2 biotech developing proteomics-based precision oncology therapies, raised $94 million by offering 7.6 million shares at $12.50, well below the range of $16 to $18. The company offered 1.7 million more shares than anticipated, and...read more
US IPO Week Ahead: IPO calendar quiets down after a relatively active week
After a relatively active week for the IPO market, the calendar is expected to quiet down again. One small deal is scheduled to price, though it is too small to be included in our IPO stats. Biotech Acrivon Therapeutics (ACRV) may also price,...read more